ACP3 LNCap clone FGC
CBP74528
詢 價(jià)
索取Protocol
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. Background | |
| ACP3 (ACPP/PAP) 全稱前列腺酸性磷酸，是應(yīng)對當(dāng)前核心療法——PSMA靶向治療——臨床耐藥挑戰(zhàn)的關(guān)鍵所在。其在前列腺組織中獨(dú)特的表達(dá)譜，為攻克腫瘤異質(zhì)性與治療耐受提供了差異化的解決路徑，是驅(qū)動下一代聯(lián)合治療與序貫治療的基石。 | |
| II. Description | |
| ACP3 LNCap clone FGC 細(xì)胞，在 LNCap clone FGC細(xì)胞的基礎(chǔ)上，穩(wěn)定表達(dá)ACP3。 | |
| III. Introduction | |
| Expressed gene: | ACP3 |
| Host Cell: | LNCap clone FGC |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+ 10% FBS + 5μg/ml Blasticidin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Binding Assay,FACS |
| IV. Representative Data | |
 Figure 1. Recombinant ACP3 LNCap clone FGC constitutively expressing ACP3. |
|
